OpRegen® Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D.
Retrieved on:
Tuesday, October 26, 2021
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Optical, Health, Clinical Trials, Safety, Bruch, AMD, VAC2, Surgeon, European Medicines Agency, U.S. Securities and Exchange Commission, Compte rendu, OCT, American Academy of Ophthalmology, RPE, Twitter, Gene, Lineage Cell Therapeutics, AAO, Therapy, David Geffen School of Medicine at UCLA, American Academy, Retinal pigment epithelium, History of the University of California, Los Angeles, Incidence, Blood, Severe cognitive impairment, Security (finance), Food, Infection, Injury, Ernest, Annual report, Company, EDT, Degenerative disease, Association, Department, Human embryonic stem cells clinical trials, Large-cell lung carcinoma, SEC, NYSE American, Geographic atrophy, Method, University, Cancer, TASE, FDA, Drusen, Forward-looking statement, Cell, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry, OpRegen, Age-Related Macular Degeneration, Lineage Cell Therapeutics, Inc., OPREGEN, AGE-RELATED MACULAR DEGENERATION, LINEAGE CELL THERAPEUTICS, INC.
, Professor, Department of Ophthalmology at the David Geffen School of Medicine at the University of California - Los Angeles.
Key Points:
- , Professor, Department of Ophthalmology at the David Geffen School of Medicine at the University of California - Los Angeles.
- The American Academy of Ophthalmology is the worlds largest association of eye physicians and surgeons.
- The mission of the American Academy of Ophthalmology is to protect sight and empower lives by serving as an advocate for patients and the public, leading ophthalmic education, and advancing the profession of ophthalmology.
- The first 3 cohorts enrolled only legally blind patients with Best Corrected Visual Acuity (BCVA) of 20/200 or worse.